

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER PRD2056USPCT U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/552527
INTERNATIONAL APPLICATION NO. PCT/EP2004/050492	INTERNATIONAL FILING DATE 8 April 2004	PRIORITY DATE CLAIMED 11 April 2003
TITLE OF INVENTION THE USE OF SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS ETC.		
APPLICANT(S) FOR DO/EO/US STECKLER, Thomas Horst Wolfgang; JANSSENS, Frans Eduard; LEENAERTS, Joseph Elisabeth; FERNANDEZ-GADEA, Francisco Javier; GOMEZ-SANCHEZ, Antonio and MEERT, Theo Frans		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 20 below concern document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. <input checked="" type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)		- INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/552527				PRD2056USPCT	
20. Other items or information: Published Application WO 2004/089372 A1 w/Search Report Attached Communication establishing Power of Attorney Express Mail Certificate					
The following fees have been submitted				CALCULATIONS	PTO USE ONLY
21.	<input checked="" type="checkbox"/>	Basic national fee (37 CFR 1.492(a)).....	\$300	\$ 300.00	
22.	<input checked="" type="checkbox"/>	Examination fee (37 CFR 1.492(c))			
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....				\$ 200.00	
All other situations.....					
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b))					
If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....					
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority.....				\$ 400.00	
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB.....					
All other situations.....					
TOTAL OF 21, 22 and 23 =				900.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		
- 100 =	/50 =		x \$250	\$ 0.00	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).				\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	14 - 20 =	0	x \$ 50	\$ 0	
Independent claims	1 - 3 =	0	x \$200	\$ 0	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360	\$ 0	
TOTAL OF ABOVE CALCULATIONS =				\$ 900.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.					
SUBTOTAL =				\$ 900.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 900.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 0.00	
				Amount to be refunded:	\$
				Amount to be charged	\$

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- 10/552527
- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 10-0750 in the amount of \$ 900.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 10-0750. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

SEND ALL CORRESPONDENCE TO:

Hal B. Woodrow, Esq.
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
U.S.A.

Hal Brent Woodrow

SIGNATURE

Hal B. Woodrow

NAME

32,501

REGISTRATION NUMBER

Docket No. PRD2056USPCT

10/552527

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas Horst Wolfgang Steckler et al.

For: THE USE OF SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE
DERIVATIVES AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS
WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY

Express Mail Certificate

"Express Mail" mailing number: EV 368 590 224 US

Date of Deposit: October 11, 2005

I hereby certify that this entry into the National Phase pursuant to 35 USC 371 contains complete application:

<input checked="" type="checkbox"/>	Express Mail Certificate	(1 page)
<input checked="" type="checkbox"/>	Return Receipt Postcard	(1 page)
<input checked="" type="checkbox"/>	PCT FORM 1390 Transmittal	(3 pages)
<input checked="" type="checkbox"/>	Copy of International Application as filed	(59 pages)
<input checked="" type="checkbox"/>	Declaration of Inventors	(8 pages)
<input checked="" type="checkbox"/>	Communication & Attachments	(6 pages)
<input checked="" type="checkbox"/>	Preliminary Amendment	(8 pages)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee; service under 37 CFR 1.10 on the date indicated above is addressed to the Mail Stop: PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450..

Laurie Phillips

(Typed or printed name of person mailing paper or fee)

/Laurie Phillips/

(Signature of person mailing paper or fee)

GENERAL INFORMATION SHEET of PRD 2056f

JC05 Rec'd PCT/PTO 11 OCT 2005

Claiming priority of: PCT Patent Application No. PCT/EP03/03879
Filing date: April 11, 2003
Title: NOVEL SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY

Title: SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY

PCT filing particulars: Application No. PCT/EP2004/050492 - WO2004/089372
Filing date: April 8, 2004

Language: English

Inventors:

1. Steckler, Thomas Horst Wolfgang
citizen of Germany
c/o: Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse
Belgium
2. Janssens, Frans Eduard
citizen of Belgium
c/o: Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse
Belgium
3. Leenaerts, Joseph Elisabeth
citizen of Belgium
c/o: Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse
Belgium
4. Fernández-Gadea, Francisco Javier
citizen of Spain
c/o: Johnson & Johnson Pharmaceutical
Research and Development
Division of Janssen-Cilag, S.A.
Calle Jarama, 75
Poligono Industrial
45007 Toledo
Spain
5. Gómez-Sánchez, Antonio
citizen of Spain
c/o: Johnson & Johnson Pharmaceutical
Research and Development
Division of Janssen-Cilag, S.A.
Calle Jarama, 75
Poligono Industrial
45007 Toledo
Spain
6. Meert, Theo Frans
citizen of Belgium
c/o: Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse
Belgium

Applicant:

Janssen Pharmaceutica N.V.
Turnhoutseweg 30
2340 Beerse Belgium

Applicant derived the right of the invention from inventor 1, 2, 3 and 4 by their contract of employment and from inventor 4 and 5 by an assignment.

10/552527

JC05 Rec'd PCT/PTO 11 OCT 2005
Docket No. PRD2056USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thomas Horst Wolfgang STECKLER et al.
Appln. No. : Not assigned Art Unit:
Filed : Herewith Examiner:
Title : THE USE OF SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-
PIPERIDINE DERIVATIVES AS SELECTIVE NON-PEPTIDE DELTA
OPIOID AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC
ACTIVITY

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COMMUNICATION

Dear Sir:

In order to establish attorneys' right to pursue the prosecution of this application under 35 CFR 3.71, attached please find a Power of Attorney or Authorization of Agent signed by the applicant Janssen Pharmaceutica N.V., as well a Statement under 37 CFR 3.73(b) stating that Janssen Pharmaceutica N.V. is the assignee of the entire right, title, and interest of the above-identified patent application, establishing same with an attached General Information Sheet, an assignment to Janssen Pharmaceutica from Janssen-Cilag S.A., and an assignment from four of the named inventors directly to Janssen Pharmaceutica N.V.

Applicant believes that the aforesaid establishes attorneys' power to prosecute this application by assignee.

Respectfully submitted,

By: /Hal Brent Woodrow/
Hal B. Woodrow
Reg. No. 32,501

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2976
Dated: October 11, 2005